Journal: Lupus science & medicine
Article Title: Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.
doi: 10.1136/lupus-2024-001446
Figure Lengend Snippet: Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
Article Snippet: Serum samples for TIMP1 (CUSABIO, Catalogue No CSB- E08003h, Wuhan, China) and THBS1 (CUSABIO, Catalogue No CSB- E08763h, Wuhan, China) were diluted 1:100 and 1:400, respectively, whereas the ICAM2 (BOSTER, Catalogue No EK0999, Peachtree Corners, Georgia) ELISA assays used serum at 1:5 dilution.
Techniques: Enzyme-linked Immunosorbent Assay, Biomarker Discovery